BPC-157 (Oral)
Also known as: Oral BPC, Stable BPC-157, GI-Specific BPC
Oral formulation of BPC-157 specifically for gastrointestinal healing and protection.
Overview
BPC-157 administered orally is particularly effective for GI-specific applications due to its remarkable stability in gastric juice. Unlike injectable forms used for systemic effects, oral BPC-157 directly targets the GI tract for conditions like ulcers, IBD, and intestinal damage.
Mechanism of Action
Same as injectable BPC-157: upregulates growth factors, promotes angiogenesis, and accelerates healing. Oral administration concentrates effects in the GI tract where it maintains stability and direct tissue contact.
Pharmacokinetics
Stable in gastric acid for 24+ hours. Local GI effects with some systemic absorption. Can be taken with or without food.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
GI Healing
250-500 mcg
2x daily
4-8 weeks
Empty stomach preferred
NSAID Protection
250 mcg
With NSAID dose
During NSAID use
Concurrent dosing
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Stable in gastric juice unlike most peptides
- 2Direct GI mucosal healing
- 3Cytoprotection against NSAID damage
- 4Effective oral bioavailability for GI
Side Effects & Contraindications
Reported Side Effects
- Generally well-tolerated
- Mild GI upset rare
Contraindications
- Active cancer (theoretical)
Safety Considerations
Same safety profile as injectable BPC-157. Research compound. Generally well-tolerated in studies.
Storage Requirements
Refrigerate for stability
Scientific References
- 1